Towards non-surgical therapy for uterine fibroids: Catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model

Human Reproduction

Volumn 26, Issue 11, 2011, Pages 3008-3018

  Hassan, M H ^a,b   Fouad, H ^c   Bahashwan, S ^b   Al Hendy, A ^d  

^a Al Azhar University   (Egypt)

^b TAIBAH UNIVERSITY   (Saudi Arabia)

^c MENOUFIA UNIVERSITY   (Egypt)

^d MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

catechol estrogen; catechol O methyl transferase inhibitor; Eker rats; estradiol; uterine leiomyomas

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; CYCLIN D1; CYCLINE; DEOXYPYRIDINOLINE; ESTROGEN; LIVER ENZYME; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ESTROGEN URINE LEVEL; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UTERUS MYOMA;

RATTUS;

EID: 80054938473     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/der280     Document Type: Article

References (92)

1. Acil Y, Brinckman J, Nothbohm H, Muller K, Batge B. Changes with age in the urinary excretion of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). Scand J Clin Lab Invest 1996;56:275-283. (Pubitemid 26169785)
2. Ahsan H, Chen Y, Whittemore AS, Kibriya MG, Gurvich I, Senie RT, Santella RM. A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk. Breast Cancer Res Treat 2004;85:121-131. (Pubitemid 38987266)
3. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 2006a;16:385-400. (Pubitemid 43923413)
4. Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006b;86:686-693. (Pubitemid 44307032)
5. Al-Hendy A, Lee EJ, Wang HQ, Copland JA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004;191:1621-1631. (Pubitemid 39491188)
6. Andreyko JL, Marshall LA, Dumesic DA, Jaffe RB. Therapeutic uses of gonadotropin releasing hormone analogs. Obstet Gynecol Surv 1987; 42:1-21. (Pubitemid 17222367)
7. Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists. Curr Med Chem 2004;11:3017-3028. (Pubitemid 39369270)
8. Auborn K, Abramson A, Bradlow HL, Sepkovic D, Mullooly V. Estrogen metabolism and laryngeal papillomatosis: a pilot study on dietary prevention. Anticancer Res 1998;18:4569-4573. (Pubitemid 29042024)
9. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7:812-821. (Pubitemid 23163585)
10. Bancroft JD, Stevens A. Theory and Practice of Histological Techniques, 4th edn. New York, USA: Churchill Livingstone. 1996.
11. Banerjee SN, Sengupta K, Banerjee S, Saxena NK, Banerjee SK. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 2003;5:417-426. (Pubitemid 37475650)
12. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91. (Pubitemid 34072969)
13. Bradlow LH. 2-Hydroxyesterone: the 'good' estrogen. J Endocrinol 1996; 150:S259-S265.
14. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;27:75-93.
15. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Invest 2003;10:161-171. (Pubitemid 36434150)
16. Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The suicide hypothesist revisited. Trends Pharmacol Sci 2002;23:122-129.
17. Colwell A, Russell RG, Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 1993;23:341-349. (Pubitemid 23168556)
18. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-438. (Pubitemid 20316570)
19. Creveling CR. The role of catechol-O-methyltransferase in the inactivation of catecholestrogen. Cell Mol Neurobiol 2003;23:289-291. (Pubitemid 36676275)
20. Davis DL, Telang NT, Osborne MP, Bradlow HL. Medical hypothesis: bifunctional genetic-hormonal pathways to breast cancer. Environ Health Perspect 1997;105:571-576. (Pubitemid 27246418)
21. Devanesan P, Todorovic R, Zhao J, Gross MI, Rogan EG, Cavalieri EL. Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: potential biomarkers for estrogeninitiated cancer. Carcinogenesis 2001; 22:489-497. (Pubitemid 32203830)
22. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 2002;441:53-62. (Pubitemid 34754249)
23. Eastell R, Colwell A, Hampton L, Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res 1997; 12:59-65. (Pubitemid 27053612)
24. Engman M, Granberg S, Williams ARW, Meng CX, Lalitkumar PGL, Gemzell-Danielsson K. Mifepristone for treatment of uterineleiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009;24:1870-1879.
25. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker CL. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995;146:1556-1567.
26. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995;768:91-100. (Pubitemid 26078723)
27. Gao Z, Matsuo H, Satoshi N, Kurachi O, Maruo T. p53 tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17B-estradiol. J Clin Endocrinol Metab 2002;87:3915-3920. (Pubitemid 34879548)
28. Goodman JE, Lavigne JA, Wu K, Helzlsouer KJ, Strickland PT, Selhub J, Yager JD. COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 2001;22:1661-1665. (Pubitemid 32952144)
29. Hamajima N, Matsuo K, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S, Oya H, Obata Y. Limited association between catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol 2001;6:13-18. (Pubitemid 32230357)
30. Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S, Fujino M. Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013, in cynomolgus monkeys. J Clin Endocrinol Metab 2003;88:1697-1704. (Pubitemid 36623391)
31. Hart R, Khalaf Y, Yeong CT, Seed P, Taylor A, Braude P. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod 2001;16:2411-2417. (Pubitemid 33054147)
32. Hassan MH, Zhang D, Salama S, Hamada F, Arafa H, Fouad H, Walker C, Al-Hendy A. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest 2009;68:19-32.
33. Hassan MH, Salama SA, Zhang D, Arafa HM, Hamada FM, Fouad H, Walker CC, Al-Hendy A. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril 2010; 93:239-250.
34. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003;116:4077-4085.
35. Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 1986;63:619-625. (Pubitemid 16050560)
36. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146:1568-1579.
37. Ignotz RA, Massague J. Transforming growth-factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular-matrix. J Biol Chem 1986;261:4337-4529.
38. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type-I collagen messenger-RNA levels by transforming growth-factor-beta. J Biol Chem 1987;262:6443-6446.
39. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998;83:427-431. (Pubitemid 28496517)
40. Ingman WV, Robertson SA. Defining the actions of transforming growth factor beta in reproduction. Bioessays 2002;24:904-914. (Pubitemid 35180845)
41. Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalili A, Rosenblatt R, Braddlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-509. (Pubitemid 27295229)
42. Kettle LM, Murphy AA, Morales AJ, Yen SC. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1998;9:116-120. (Pubitemid 24203934)
43. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol 2002;76:643-649. (Pubitemid 35471789)
44. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986;166:209-219. (Pubitemid 16030469)
45. Lane DP. Cancer-p53, guardian of the genome. Nature 1992; 358:15-16.
46. Lavigne JA, Goodman JE, Fonong T, Odwin S, He P, Roberts DE, Yager JD. The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Res 2001;61:7488-7494. (Pubitemid 32995038)
47. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003;72:877-883. (Pubitemid 35454133)
48. Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptorpositive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265-275. (Pubitemid 38553758)
49. Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev 2002;7:112-129. (Pubitemid 34461523)
50. Loy CJ, Evelyn S, Lim FK, Liu MH, Yong EL. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod 2005; 11:561-566. (Pubitemid 41488018)
51. Lumsden MA, Wallace EM. Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998;12:177-195. (Pubitemid 28456986)
52. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther 1993;57:237-257. (Pubitemid 23175382)
53. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004; 10:207-220. (Pubitemid 38750141)
54. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78:1250-1255. (Pubitemid 28479160)
55. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, Moorman PG, Boissy RJ, Bell DA. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998;19:1943-1947. (Pubitemid 28521935)
56. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A. Polymorphic catechol-O- methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:635-640. (Pubitemid 32703197)
57. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990;11:443-453. (Pubitemid 20261695)
58. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiol 2000;11:635-640.
59. Othman ER, Salama SA, Ismail N, Al-Hendy A. Gene therapy of endometriosis: adenovirus mediated expression of dominant negative estrogen receptor induces apoptosis in human endometriotic cells. Fertil Steril 2007;88:462-471. (Pubitemid 47212127)
60. Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982;143:130-133. (Pubitemid 12104979)
61. Persson I. The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies. Acta Obstet Gynecol Scand Suppl 1985;130:59-66. (Pubitemid 15058119)
62. Payne JF, Haney AF. Serious complications of uterine artery embolization for conservative treatment of fibroids. Fertil Steril 2003;79:128-131. (Pubitemid 36071250)
63. Pfaffl MW. A new mathematical model for relative quantifications in real-time RT-PCR. Nucleic Acids Res 2001;29:2002-2007.
64. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids 1981;37:195-203.
65. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14-18.
66. Reitman S, Frankel SA. Colormetric method for the determination of serum glutamic oxalocetic and glutamic pyruvic transaminases. A J Clin Path 1957;28:56-63.
67. Salama SA, Ho S, Wang H, Tenhunen J, Tilgmann C, Al-Hendy A. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril 2006;86:259-262. (Pubitemid 43977765)
68. Salama SA, Jamaluddin M, Kumar R, Hassan MH, Al-Hendy A. Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: distinct effect of progesterone receptor isoforms. J Steroid Biochem Mol Biol 2007;107:253-261. (Pubitemid 47380375)
69. Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:655-676. (Pubitemid 351804125)
70. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): a rodent model of Lassa fever. Am J Trop Med Hyg 2006;74:1096-1102. (Pubitemid 351627423)
71. Seibel MJ, Woitge HW, Farahmand I, Oberwittler H, Ziegler R. Automated and manual assays for urinary crosslinks of collagen: Which assay to use? Exp Clin Endocrinol Diabetes 1998;106:143-148. (Pubitemid 28209742)
72. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000;50:273-279. (Pubitemid 30441278)
73. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-328. (Pubitemid 34832256)
74. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 2002;78:1-12. (Pubitemid 34722662)
75. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril 2001;75:405-410. (Pubitemid 32112122)
76. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res 2005;11:1722-1732. (Pubitemid 40471833)
77. Taioli E, Garte SJ, Trachman J, Garbers S, Sepkovic DW, Osborne MP, Mehi S, Bradlow HL. Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 1996;88:617. (Pubitemid 26137585)
78. Thirunavukkarasu C, Sakthisekaran D. Effect of selenium on N-nitrosodiethylamine-induced multistage hepatocarcinogenesis with reference to lipid peroxidation and enzymic antioxidants. Cell Biochem Funct 2001;19:27-35. (Pubitemid 32178742)
79. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998;58:2107-2110. (Pubitemid 28232895)
80. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16alphahydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-1072. (Pubitemid 29293046)
81. Vandewalle B. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-246. (Pubitemid 19038903)
82. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-246. (Pubitemid 19038903)
83. VeKaut BS. Changing trends in treatment of leiomyomata uteri [abstract]. Curr Opin Obstet Gynecol 1993;5:301.
84. Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I, Magnusson C. Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis 2003;24:681-687. (Pubitemid 36592403)
85. Wen W, Cai Q, Shu XO, Cheng JR, Parl F, Pierce L, Gao YT, Zheng W. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the shanghai breast cancer study and a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:329-335. (Pubitemid 40270093)
86. Wentz MJ, Jamaluddin M, Garfield RE, Al Hendy A. Regulation of catechol-O-methyltransferase expression in human myometrial cells. Obstet and Gyn 2006;108:1439-1447. (Pubitemid 44901019)
87. Wentz MJ, Shi S, Shi L, Salama SA, Harirah HM, Fouad H, Garfield RE, Al-Hendy A. Treatment with an inhibitor of catechol-O-methyltransferase activity reduces preterm birth and impedes cervical resistance to stretch in pregnant rats. Reprod 2007; 134:831-839.
88. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994; 83:549-555.
89. Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl 1997;29:111-116. (Pubitemid 28246634)
90. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP. Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg 2001;124:241-247. (Pubitemid 32230512)
91. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG et al. Genotoxic metabolites of estradiol in breast: potential mechanisms of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003; 86:477-486. (Pubitemid 37412587)
92. Zhu BT, Liehr JG. Inhibition of the catechol-O-methyltransferase- catalyzed O-methylation of 2-and 4-hydroxyestradiol by catecholamine: implications for the mechanism of estrogen-induced carcinogenesis. Arch Biochem Biophys 1993;304:248-256. (Pubitemid 23214178)